CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dae Hwa Pharm Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dae Hwa Pharm Co Ltd
495, Hanu-ro, Hoengseong-eup
Phone: +82 25866451p:+82 25866451 HOENGSEONG, 25228  South Korea Ticker: 067080067080
Business Summary
Dae Hwa Pharm Co Ltd is a Korea-based company primarily engaged in the manufacturing and sales of pharmaceuticals. The Company operates through five segments. The Pharmaceutical Manufacturing and Sale segment primarily manufactures and sells Cephamethyl Tablets, Magnes Tablets, Frospan Tablets, and Amalienne. The Pharmaceutical Wholesale segment primarily wholesales Trulicity, Provigil Tablets, Atozet Tablets, and Viread Tablets. The Medical Information System segment primarily provides Mediframe services and content production. The Pharmaceutical Raw Materials Manufacturing and Sale segment primarily manufactures and sells Methylol Cephalex in Lysinate, Sodium Loxoprofen, Phloroglucinol, Sodium Hyaluronate, and Amalienne. The Cosmetics and Medical Device Manufacturing and Sale segment primarily manufactures and sells dermal fillers and Amalienne.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
3842 Orthopedic, prosthetic, and surgical appliances and supplies
5122 Drugs, drug proprietaries, and druggists' sundries
2869 Industrial organic chemicals, not elsewhere classified
2844 Perfumes, cosmetics, and other toilet preparations
7375 Information retrieval services
7373 Computer integrated systems design
7389 Business services, not elsewhere classified
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Han GuLee 70 8/14/2013 8/8/2006
Managing Director Gwon SeokHan 60 1/1/2008 1/1/2007
Managing Director Byeong YunHwang 58
6 additional Officers and Directors records available in full report.

Business Names
Business Name
067080
Daehwa Pharm Co., Ltd.

General Information
Number of Employees: 424 (As of 9/30/2023)
Outstanding Shares: 17,516,650 (As of 9/30/2025)
Shareholders: 15,820
Stock Exchange: KDQ
Fax Number: +82 25870566


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, February 1, 2026